Product Review - Obinutuzumab in follicular lymphoma

This review discusses the evidence in support of the use of obinutuzumab, its pharmacological properties, dosage and administration, and efficacy and tolerability as demonstrated in pivotal clinical trials.

It also provides commentary and recommendations from Professor John Seymour AM, a clinical haematologist and Associate Director of Clinical Research at the Peter MacCallum Centre.


Please login below to download this issue (PDF)